$3.51
1.54% today
Nasdaq, Jul 15, 07:50 pm CET
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Relay Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Relay Therapeutics Inc Classifications & Recommendation:

Buy
84%
Hold
16%

Relay Therapeutics Inc Price Target

Target Price $14.28
Price $3.56
Potential
Number of Estimates 13
13 Analysts have issued a price target Relay Therapeutics Inc 2026 . The average Relay Therapeutics Inc target price is $14.28. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 19 analysts: 16 Analysts recommend Relay Therapeutics Inc to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Relay Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Relay Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 10.01 11.77
60.82% 17.55%
EBITDA Margin -3,666.33% -3,281.35%
154.74% 10.50%
Net Margin -3,373.73% -2,760.21%
152.07% 18.19%

14 Analysts have issued a sales forecast Relay Therapeutics Inc 2025 . The average Relay Therapeutics Inc sales estimate is

$11.8m
Unlock
. This is
53.22% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$39.6m 415.43%
Unlock
, the lowest is
$7.5m 2.02%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $10.0m 60.82%
2025
$11.8m 17.55%
Unlock
2026
$11.7m 0.22%
Unlock
2027
$22.4m 90.74%
Unlock
2028
$34.5m 54.26%
Unlock
2029
$142m 309.62%
Unlock
2030
$300m 112.32%
Unlock
2031
$559m 86.21%
Unlock
2032
$726m 29.75%
Unlock

6 Analysts have issued an Relay Therapeutics Inc EBITDA forecast 2025. The average Relay Therapeutics Inc EBITDA estimate is

$-386m
Unlock
. This is
6.75% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-395m 9.08%
Unlock
, the lowest is
$-376m 4.04%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-367m 0.20%
2025
$-386m 5.21%
Unlock
2026
$-392m 1.59%
Unlock
2027
$-348m 11.15%
Unlock
2028
$-274m 21.23%
Unlock
2029
$-48.8m 82.23%
Unlock
2030
$85.8m 275.85%
Unlock
2031
$268m 212.85%
Unlock
2032
$367m 36.92%
Unlock

EBITDA Margin

2024 -3,666.33% 154.74%
2025
-3,281.35% 10.50%
Unlock
2026
-3,340.78% 1.81%
Unlock
2027
-1,556.12% 53.42%
Unlock
2028
-794.55% 48.94%
Unlock
2029
-34.48% 95.66%
Unlock
2030
28.55% 182.80%
Unlock
2031
47.97% 68.02%
Unlock
2032
50.62% 5.52%
Unlock

14 Relay Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Relay Therapeutics Inc net profit estimate is

$-325m
Unlock
. This is
2.58% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-220m 33.96%
Unlock
, the lowest is
$-369m 10.75%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-338m 1.25%
2025
$-325m 3.83%
Unlock
2026
$-317m 2.32%
Unlock
2027
$-325m 2.50%
Unlock
2028
$-228m 29.77%
Unlock
2029
$-151m 33.76%
Unlock
2030
$-36.5m 75.86%
Unlock
2031
$184m 604.71%
Unlock
2032
$257m 39.63%
Unlock

Net Margin

2024 -3,373.73% 152.07%
2025
-2,760.21% 18.19%
Unlock
2026
-2,702.02% 2.11%
Unlock
2027
-1,451.99% 46.26%
Unlock
2028
-661.04% 54.47%
Unlock
2029
-106.91% 83.83%
Unlock
2030
-12.15% 88.64%
Unlock
2031
32.94% 371.11%
Unlock
2032
35.45% 7.62%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.36 -1.91
15.41% 19.07%
P/E negative
EV/Sales negative

14 Analysts have issued a Relay Therapeutics Inc forecast for earnings per share. The average Relay Therapeutics Inc EPS is

$-1.91
Unlock
. This is
2.55% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.29 34.18%
Unlock
, the lowest is
$-2.17 10.71%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.36 15.41%
2025
$-1.91 19.07%
Unlock
2026
$-1.86 2.62%
Unlock
2027
$-1.91 2.69%
Unlock
2028
$-1.34 29.84%
Unlock
2029
$-0.89 33.58%
Unlock
2030
$-0.21 76.40%
Unlock
2031
$1.08 614.29%
Unlock
2032
$1.51 39.81%
Unlock

P/E ratio

Current -1.82 3.68%
2025
-1.87 2.96%
Unlock
2026
-1.91 2.14%
Unlock
2027
-1.87 2.09%
Unlock
2028
-2.66 42.25%
Unlock
2029
-4.01 50.75%
Unlock
2030
-16.62 314.46%
Unlock
2031
3.29 119.80%
Unlock
2032
2.36 28.27%
Unlock

Based on analysts' sales estimates for 2025, the Relay Therapeutics Inc stock is valued at an EV/Sales of

-8.50
Unlock
and an P/S ratio of
51.87
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -13.02 295.20%
2025
-8.50 34.72%
Unlock
2026
-8.52 0.22%
Unlock
2027
-4.47 47.57%
Unlock
2028
-2.90 35.18%
Unlock
2029
-0.71 75.59%
Unlock
2030
-0.33 52.90%
Unlock
2031
-0.18 46.29%
Unlock
2032
-0.14 22.93%
Unlock

P/S ratio

Current 79.47 341.39%
2025
51.87 34.73%
Unlock
2026
51.98 0.22%
Unlock
2027
27.25 47.57%
Unlock
2028
17.67 35.18%
Unlock
2029
4.31 75.59%
Unlock
2030
2.03 52.90%
Unlock
2031
1.09 46.30%
Unlock
2032
0.84 22.94%
Unlock

Current Relay Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Guggenheim
Locked
Locked
Locked May 07 2025
Wells Fargo
Locked
Locked
Locked Apr 17 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 07 2025
Stifel
Locked
Locked
Locked Feb 27 2025
Goldman Sachs
Locked
Locked
Locked Feb 27 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 14 2025
JMP Securities
Locked
Locked
Locked Dec 12 2024
Analyst Rating Date
Locked
Guggenheim:
Locked
Locked
May 07 2025
Locked
Wells Fargo:
Locked
Locked
Apr 17 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 07 2025
Locked
Stifel:
Locked
Locked
Feb 27 2025
Locked
Goldman Sachs:
Locked
Locked
Feb 27 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 14 2025
Locked
JMP Securities:
Locked
Locked
Dec 12 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today